Highbridge Capital Management Lowers stake in Medivation Inc (MDVN)

Medivation Inc (MDVN) : Highbridge Capital Management reduced its stake in Medivation Inc by 14.93% during the most recent quarter end. The investment management company now holds a total of 680,488 shares of Medivation Inc which is valued at $44,925,818 after selling 119,389 shares in Medivation Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Medivation Inc makes up approximately 1.21% of Highbridge Capital Management’s portfolio.

Other Hedge Funds, Including , Schwab Charles Investment Management Inc boosted its stake in MDVN in the latest quarter, The investment management firm added 23,338 additional shares and now holds a total of 397,275 shares of Medivation Inc which is valued at $26,228,096. Medivation Inc makes up approx 0.03% of Schwab Charles Investment Management Inc’s portfolio. Tredje Ap-fonden sold out all of its stake in MDVN during the most recent quarter. The investment firm sold 640 shares of MDVN which is valued $42,253. Indexiq Advisors added MDVN to its portfolio by purchasing 137,448 company shares during the most recent quarter which is valued at $9,074,317. Medivation Inc makes up approx 0.53% of Indexiq Advisors’s portfolio.

Medivation Inc opened for trading at $80.45 and hit $80.98 on the upside on Thursday, eventually ending the session at $80.93, with a gain of 0.46% or 0.37 points. The heightened volatility saw the trading volume jump to 67,00,788 shares. Company has a market cap of $13,429 M.

On the company’s financial health, Medivation Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.26. The company had revenue of $206.20 million for the quarter, compared to analysts expectations of $209.92 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 EPS.

Many Wall Street Analysts have commented on Medivation Inc. Medivation Inc was Downgraded by Stifel to ” Hold” on Aug 23, 2016. Medivation Inc was Downgraded by Credit Suisse to ” Neutral” on Aug 23, 2016. Company shares were Downgraded by Maxim Group on Aug 23, 2016 to ” Hold”, Firm has raised the Price Target to $ 81.50 from a previous price target of $76 .

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Leave a Reply

Medivation Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Medivation Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.